Evotec (NASDAQ:EVO - Get Free Report) had its price target decreased by stock analysts at HC Wainwright from $14.00 to $11.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective would suggest a potential upside of 115.69% from the company's current price.
Other analysts also recently issued reports about the stock. Royal Bank of Canada upgraded shares of Evotec from a "sector perform" rating to an "outperform" rating in a report on Thursday, January 18th. Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "hold" rating to a "buy" rating in a report on Friday, April 12th.
Check Out Our Latest Stock Analysis on Evotec
Evotec Stock Down 2.5 %
EVO stock traded down $0.13 during mid-day trading on Thursday, hitting $5.10. The company had a trading volume of 649,314 shares, compared to its average volume of 96,962. Evotec has a 12-month low of $4.87 and a 12-month high of $13.49. The company has a 50-day moving average price of $7.33 and a 200 day moving average price of $8.67.
Hedge Funds Weigh In On Evotec
Several hedge funds have recently added to or reduced their stakes in EVO. Quadrant Capital Group LLC bought a new position in Evotec in the 4th quarter worth about $25,000. Optiver Holding B.V. grew its stake in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company's stock worth $945,000 after acquiring an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC bought a new position in Evotec in the 4th quarter worth about $53,931,000. 5.81% of the stock is currently owned by institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
